Physician profile
Alaa Owainati
NPI 1861483620
$6,491.56
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $1,541 · 2021: $782 · 2022: $896 · 2023: $1,671 · 2024: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,350 · Education: $13.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,349.55 |
| Education | $13.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $920.52 | 2020-2022 | |
| Coherus Oncology, INC. | $810.27 | 2020-2024 | |
| Astrazeneca Pharmaceuticals Lp | $621.38 | 2019-2024 | Fasenra, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $458.48 | 2019-2024 | Opdivo |
| Janssen Biotech, INC. | $370.61 | 2019-2024 | Darzalex, Tecvayli, Imbruvica |
| Amgen INC. | $337.89 | 2019-2023 | Lumakras, Nplate, Xgeva |
| Celgene Corporation | $272.05 | 2019-2023 | Pomalyst |
| Pfizer INC. | $261.96 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $228.95 | 2019-2024 | Keytruda, Welireg |
| Lilly USA, LLC | $178.81 | 2019-2024 | Verzenio |
| Genentech USA, INC. | $172.24 | 2019-2023 | Venclexta |
| Astellas Pharma US INC | $132.71 | 2020-2023 | Padcev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.48 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.95 | 2019-2023 | Iclusig, Ninlaro |
| Daiichi Sankyo INC. | $109.56 | 2019-2024 | Enhertu |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $102.93 | 2021-2023 | |
| Incyte Corporation | $101.70 | 2019-2023 | Jakafi |
| Eisai INC. | $98.40 | 2020-2024 | |
| Glaxosmithkline, LLC. | $98.36 | 2020-2023 | Shingrix, Jemperli, Zejula |
| Novartis Pharmaceuticals Corporation | $93.84 | 2021-2024 | |
| Aveo Pharmaceuticals, INC. | $87.55 | 2021-2024 | Fotivda |
| Gilead Sciences, INC. | $78.07 | 2022-2023 | Trodelvy |
| Seagen INC. | $66.62 | 2019-2023 | Padcev |
| Tersera Therapeutics LLC | $64.41 | 2019-2024 | Zoladex |
| Dova Pharmaceuticals | $56.62 | 2019-2020 | |
| Array Biopharma INC | $55.10 | 2022-2024 | Braftovi, Mektovi, Lorbrena |
| Inari Medical, INC. | $52.64 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Taiho Oncology, INC. | $41.13 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $36.73 | 2019-2021 | |
| Emd Serono, INC. | $36.52 | 2019-2022 | |
| Mylan Institutional INC. | $33.05 | 2019 | |
| Abbvie INC. | $29.73 | 2023 | |
| Pharmaessentia USA Corporation | $27.37 | 2024 | Besremi |
| Acrotech Biopharma INC. | $25.55 | 2022 | |
| Deciphera Pharmaceuticals INC. | $20.64 | 2023 | Qinlock |
| G1 Therapeutics, INC. | $19.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.68 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $19.44 | 2024 | Somatuline Depot, Onivyde |
| Pharmacosmos Therapeutics INC. | $19.40 | 2023 | Monoferric |
| Adaptive Biotechnologies Corporation | $19.08 | 2022 | |
| Kite Pharma, INC. | $18.11 | 2023 | |
| Puma Biotechnology, INC. | $15.82 | 2019 | |
| Apellis Pharmaceuticals, INC. | $15.75 | 2023 | Empaveli |
| Clovis Oncology, INC. | $14.76 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alaa Owainati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.